Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective, unmasked, randomized evaluation of the iStent in patients with primary open-angle glaucoma. Patients will be randomized to one of two groups: 1) iStent, or 2) medication.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Glaukos Corporation
• Treatments: Antihypertensive Agents; Latanoprost; Timolol

Criteria

Inclusion Criteria:

• Diagnosis of primary open-angle glaucoma

• Male or female at least 18 years of age and able to provide written informed consent

• Mean IOP (at baseline visit after washout of any medications) must be 22 mm Hg and no greater than 38 mm Hg

• Likely to be available and willing to attend follow-up visits

Exclusion Criteria:

• Angle closure glaucoma

• Secondary glaucomas

• Prior glaucoma procedures

• Elevated episcleral venous pressure from history of active thyroid orbitopathy, carotid-cavernous fistula, orbital tumors, or orbital congestive disease